Last reviewed: 2026-04-16
Key Takeaway
Between September 2025 and March 2026, the FDA sent more than 85 warning letters to GLP-1 telehealth companies and online sellers. Hims & Hers, MEDVi, Bliv Wellness, FitRX, and dozens of others were cited for misleading claims about compounded semaglutide and tirzepatide. FormBlends has received zero warning letters.
If you buy compounded GLP-1 medication online, the FDA probably has opinions about the company selling it to you. In the past seven months, the agency has run the biggest enforcement wave in telehealth history. This tracker lists every named company, the violations, and what it means for patients who still want a legitimate compounded option.
For deeper context on how the market got here, see our State of GLP-1 Telehealth 2026 report.
Why did the FDA start cracking down on GLP-1 telehealth?
The crackdown traces back to one decision. On February 21, 2025, the FDA declared the injectable semaglutide shortage resolved. That ended the legal window that let 503A and 503B pharmacies sell compounded copies of Wegovy and Ozempic.
503A pharmacies had until April 22, 2025 to stop. 503B outsourcing facilities had until May 22, 2025. After those dates, most compounding of semaglutide became an illegal sale of an unapproved drug, unless a patient had a documented clinical reason a brand version wouldnt work.
Plenty of telehealth platforms didnt stop. Novo Nordisk commissioned independent testing on compounded samples pulled from the market and reported 86% impurities in some injectable vials and 75% in oral forms. That data gave the FDA exactly the kind of public safety angle it needed to justify a sweep.
The pressure wasnt only regulatory. Throughout 2024 and early 2025, emergency rooms reported dosing errors from patients using unclear compounded vials, sometimes taking ten times the intended dose because the concentration was different from what their previous pharmacy supplied. Those incidents fed congressional inquiries, which fed FDA enforcement priorities.
By September 2025, the agency had built up enough case files, testing data, and political cover to move on dozens of companies at once.
Which companies received FDA warning letters?
Heres the running tracker. Dates are when the warning letter was issued. The table covers the most cited names; the full 85+ letter list is on the FDAs public warning letter database.
| Company | Date | Primary violation cited |
|---|---|---|
| Hims & Hers | Sept 2025; escalation Feb 2026 | Comparing compounded to FDA-approved Wegovy in DTC ads |
| Bliv Wellness | Sept 2025 | Claiming same active ingredient as FDA-approved products |
| Belle Health | Sept 2025 | Misleading advertising of compounded semaglutide |
| FitRX | Sept 2025 | Implying the company compounds its own drugs |
| BluefitMD | Sept 2025 | Unapproved new drug claims |
| Viv Health | Sept 2025 | Comparative efficacy claims vs Ozempic |
| 24HrDoc | Sept 2025 | Misbranding of compounded injectables |
| GoodGirlRx | Sept 2025 | Direct-to-consumer ad violations |
| MEDVi | Feb 2026 | Misbranding |
| 30 additional telehealth sellers | March 2026 | Mixed: unapproved drug sales, equivalency claims, misbranding |
The September 2025 wave alone hit 55+ online sellers in a single coordinated action. For a cleaner view of which providers have stayed clean, check the FormBlends provider directory.
A few patterns show up in the letter sample. Most named companies were pure-play weight-loss telehealth, not general primary-care platforms. Most used paid social advertising featuring before-and-after photos. And most listed a single partner pharmacy, often a 503A facility in Florida, Texas, or Nevada, that also showed up in other companies warning letters.
What specific claims did the FDA cite as violations?
Four claim categories show up in almost every letter. If you see a telehealth site doing any of these today, thats a red flag the FDA hasnt gotten to them yet.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Comparing compounded drugs to FDA-approved brands. Saying your compounded semaglutide works like Wegovy, or showing side-by-side efficacy charts from brand clinical trials, is an unapproved drug claim. The FDA treats brand trial data as brand marketing, full stop.
Claiming "same active ingredient" as FDA-approved. Even if the molecule is identical, a compounded product isnt the approved drug. The FDA letters call this a misleading equivalency claim because compounded products havent gone through Novo Nordisks or Lillys manufacturing controls.
Implying the telehealth brand compounds the drugs. Most telehealth platforms arent pharmacies. They contract with 503A or 503B facilities. Marketing language like "our compounded formula" blurs that line and triggers FDA concern about who actually holds legal responsibility for the product.
Misleading direct-to-consumer advertising. This is the catch-all. Testimonials without risk disclosure, dosing charts lifted from brand labels, and promises about weight-loss timelines all fall into this bucket.
For a plain-English comparison of compounded vs brand options, read compounded vs brand-name GLP-1 medications.
What happened after Hims received its warning letter?
Hims & Hers is the highest-profile case. The company received a warning letter in September 2025, then got an escalation notice in February 2026 that specifically mentioned "seizure and injunction" as possible next steps if it didnt correct the cited violations.
Seizure means the FDA can physically take product from warehouses. Injunction means a federal court order forcing the company to stop specific practices, with contempt penalties if it keeps going. Neither has happened yet, but the language itself moved Hims stock and forced public statements from the company about changes to its weight-loss marketing.
What changed on the Hims site after February 2026 was mostly language. Direct comparisons to Wegovy got softer. Testimonial pages added more risk disclosures. The core business, compounded semaglutide delivered through contracted pharmacies, kept running. That gap between enforcement talk and on-the-ground practice is why patients still have to do their own vetting.
Industry analysts pointed out something else. The escalation letter landed the same week Novo Nordisk filed civil suits against several compounding pharmacies for trademark and false-advertising claims. The parallel pressure, federal agency plus brand manufacturer, left companies fighting on two legal fronts at once.
How does this affect your choice of GLP-1 provider?
A warning letter isnt a shutdown. Its a formal notice that says "fix this or we escalate." Most companies respond, adjust marketing, and keep selling. But the letters tell you which providers were willing to cross lines to grow faster, and that pattern matters when youre trusting them with an injectable.
Three things to look for when picking a provider:
- A clean FDA warning letter record. You can search the FDA public database by company name.
- Clear sourcing. The provider should tell you which 503A or 503B pharmacy fills your prescription, not hide it.
- Honest marketing. If the site compares itself to Wegovy or Zepbound head-to-head in efficacy charts, theyre doing exactly what the FDA cited in 85+ letters.
FormBlends hasnt received a warning letter. Our product pages avoid the four claim categories the FDA flagged, and we publish our pharmacy partners openly.
What should patients do if their provider got a warning letter?
First, dont panic and stop mid-cycle. Abruptly discontinuing a GLP-1 can cause rapid weight regain and blood-sugar swings, especially for patients using it for type 2 diabetes. Talk to the prescribing clinician before changing anything.
Second, ask the provider two questions: what specifically did the FDA cite, and what changed in response? A legitimate company will answer both. A sketchy one will give you PR language and no specifics.
Third, if the answers feel thin, transfer care. You can book a consultation with a clean provider like FormBlends through our intake process, and most platforms can continue your existing dose with a new prescription after reviewing records.
Fourth, save everything. Keep screenshots of the providers current marketing, your order confirmations, your lot numbers, and any medical records tied to your prescription. If an FDA action later escalates or a class action forms, that documentation is what puts you inside the plaintiff class.
Fifth, check your credit card statements. A few platforms in the September 2025 wave kept charging subscriptions after pausing shipments, or quietly switched patients to different compounded formulas without consent. Dispute unclear charges, and ask in writing what product youre actually receiving on your next shipment.
Frequently asked questions
Does an FDA warning letter mean a company is shut down?
No. A warning letter is a formal notice demanding corrective action within 15 working days. The company keeps operating while it responds. Escalation to seizure or injunction is possible but rare. Only a handful of the 85+ letters have moved past the warning stage.
Is it still legal to buy compounded semaglutide in 2026?
In narrow cases, yes. A 503A pharmacy can compound for an individual patient who has a documented clinical reason they cant use the FDA-approved version, for example a documented allergy to an inactive ingredient in Wegovy. Mass-market compounding of identical copies became illegal after April 22, 2025.
Why did Novo Nordisk fund impurity testing?
Novo Nordisk makes Ozempic and Wegovy, so it has a direct commercial interest in ending compounded competition. That said, the 86% impurity finding on injectable samples and 75% on oral samples came from independent labs and has been cited in FDA communications. The funding source doesnt invalidate the data, but its worth knowing.
Has FormBlends received any FDA warning letters?
No. FormBlends has zero warning letters as of April 2026. We avoid comparative claims against FDA-approved products, we disclose our pharmacy partners, and our clinical intake screens out patients who would be better served by brand medication.
What happens if I ordered from a company that got a letter?
Your existing supply is almost always fine to use; warning letters target marketing and manufacturing practices, not finished product recalls. If the FDA issues a recall on a specific lot, that notice comes separately. Check your bottles lot number against current FDA recall lists, and finish the dose youre on unless your clinician says otherwise.
Can I sue a telehealth company that sold me a product with impurities?
Potentially, though product liability cases for compounded drugs are legally messy because compounding pharmacies have different liability exposure than brand manufacturers. Document your lot numbers, save your shipping records, and talk to a pharmaceutical product liability attorney if you believe you were harmed. The FDA warning letter itself isnt a finding of patient harm, but its admissible in civil cases.
Will the FDA keep issuing warning letters in 2026?
Yes, based on public agency statements. The March 2026 wave of 30 letters was described as the start of a "second phase" focused on telehealth companies rather than pharmacies. Expect more letters through the rest of the year, especially targeting platforms that kept running mass-market compounding after the shortage ended.
Where can I see the full list of 85+ letters?
The FDAs public warning letter database is searchable by company name and date. You can filter by "compounded" or "semaglutide" to pull the GLP-1 specific letters. Our State of GLP-1 Telehealth 2026 report also includes an appendix with every letter linked.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting, stopping, or switching any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation.